Atlanticus Holdings is a holding company. Through its subsidiaries, the company provides various credit and related financial services and products. The company has two segments: Credit and Other Investments, whereby the company supports lenders who originate consumer loan products that include retail credit and credit cards marketed through various channels, including retail point-of-sale, direct mail solicitation, and partnerships with third parties; and Auto Finance, which purchases and/or services loans secured by automobiles from or for, and also provides floor plan financing for, a pre-qualified network of automotive dealers and automotive finance companies in the buy-here, pay-here, used car business.
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.
Overseas Shipholding Group is a holding company. Through its subsidiaries, the company owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products in the U.S. Flag trades. The company has one reportable business segment. The company's U.S. Flag Fleet consists of various owned and chartered-in Jones Act Handysize Product Carriers and Articulated Tug Barges and non-Jones Act U.S. Flag Handysize Product Carriers that participate in the U.S. Maritime Security Program. Under the Jones Act, shipping between U.S. ports, including the movement of Alaskan crude oil to U.S. ports, is reserved for U.S. Flag vessels.
Saratoga Investment is registered as non-diversified closed end management investment company and a business development company. The company's investment objective is to generate income and, to a lesser extent, capital appreciation from its investments. The company's portfolio is comprised primarily of investments in leveraged loans issued by middle market companies.
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.